Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: drotrecogin label

REGULATORY INTERACTIONS  – 1

Posted on July 6, 2025 by Harald — No Comments ↓

It can feel like the mountain stage of the Tour de France… A lot of effort goes into preparing for meetings with Regulators.  There is also a lot we can learn at such meetings. Today we start a series of blogs detailing personal experiences and learnings, highlighting do’s and don’ts. Continue reading REGULATORY INTERACTIONS  – 1→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on WhatsApp (Opens in new window) WhatsApp

Like this:

Like Loading...
Posted in Did you know...?, The News, The Viewpoint | Tagged Allphase Pharma Consulting, ansm, BfArM, CDE, drotrecogin label, EMA, FDA, Harald Reinhart, Health Canada, ICH, Lilly, NMPA, PMDA, post-approval commitment, regional regulatory differences, regulatory meeting preparation, SwissMedic, TGA, Xigris | Leave a reply

Go back

Your message has been sent

Rating(required)
Warning

Footer Menu

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2026 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d